Overview

Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose is to evaluate the safety and efficacy of recombinant humanized anti-IgE monoclonal antibody injection in patients with allergic asthma.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shanghai Zhangjiang Biotechnology Limited Company
Treatments:
Antibodies
Antibodies, Monoclonal
Omalizumab